How much revenue does the gastrointestinal therapeutics market generate?

The market size of gastrointestinal therapeutics in 2027 is calculated to be USD 45.08 billion.

What is the forecasted size of the gastrointestinal therapeutics industry?

Gastrointestinal Therapeutics Market size was worth USD 44.3 billion in 2026 and is expected to grow at a 2.09% CAGR between 2027 and 2036, surpassing USD 54.48 billion by 2036.

What is driving the increasing adoption of generics in gastrointestinal therapeutics purchasing behavior?

Generics are gaining traction due to growing cost sensitivity across healthcare systems and patients requiring long-term therapy. Their affordability supports wider treatment access, particularly in high-volume indications, shifting purchasing decisions toward lower-cost alternatives within the gastrointestinal therapeutics market.

How are biologics and targeted therapies influencing treatment pathways in chronic gastrointestinal disease management?

Biologics and targeted therapies are improving disease control in complex conditions like IBD by enabling better remission and more tailored treatment strategies. This is shifting prescribing toward higher-value specialty care and increasing reliance on structured, long-term disease management approaches.

Why do branded therapies lead the gastrointestinal therapeutics market?

Branded therapies accounted for 65.61% of the market in 2026 due to strong physician familiarity, established efficacy profiles, and continued preference for trusted treatments in complex gastrointestinal conditions.

Which route of administration is growing the fastest in the gastrointestinal therapeutics market?

Injectable therapies are the fastest-growing route because they support targeted and closely managed treatment for patients requiring greater clinical control than oral therapies can provide.

Why does North America lead the gastrointestinal therapeutics market?

North America accounted for 39.90% of the market in 2026, supported by established treatment infrastructure, broad therapy access, major pharmaceutical presence, and well-developed reimbursement systems.

What is driving gastrointestinal therapeutics market growth in Asia Pacific?

Asia Pacific is projected to grow at a 3.88% CAGR as healthcare access improves, diagnosis rates increase, and expanding hospital and pharmacy networks strengthen therapy adoption.

What are the prominent companies operating in the gastrointestinal therapeutics landscape?

Leading companies in the gastrointestinal therapeutics market include AbbVie Inc. (United States), AstraZeneca PLC (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (United States), Bayer AG (Germany), Johnson & Johnson (United States), Salix Pharmaceuticals, Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Gilead Sciences, Inc. (United States), Cipla Limited (India).